Carnosine vs Humanin
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Carnosine
Naturally occurring dipeptide (β-alanine + L-histidine) found at high concentrations in skeletal muscle and brain. Functions as a pH buffer, anti-glycation agent, antioxidant, and metal chelator. Extensively studied for athletic performance (pH buffering), neuroprotection, anti-aging (AGE formation prevention), and cataract research (eye drops).
Full profileHumanin
Humanin is a 21-amino acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of the mitochondrial genome — discovered in 2001 through a screen for neuroprotective factors in Alzheimer's disease. It is the founding member of a new class of peptide hormones encoded by mitochondria, not nuclear DNA. Circulating humanin levels decline sharply with age and are inversely correlated with cardiovascular disease risk, insulin resistance, and cognitive decline.
Full profile| Carnosine | Humanin | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | β-alanyl-L-histidine, L-carnosine, brain dipeptide, muscle dipeptide | HN, HNG (Gly14-Humanin — more potent analog), Mitochondrial-derived peptide |
| Evidence | Research-stage | Research-stage |
| Dosing range | 500mg–2000mg mg, twice daily oral | 100mcg–2mg mcg, Daily or 3–5x weekly |
| Administration | Oral (capsule/powder), Topical (eye drops — cataract research) | Subcutaneous injection, Intranasal (for CNS applications), Intravenous (clinical studies) |
| Key side effects | Generally well-tolerated, Mild GI discomfort at high doses (>2g/day), Rare: carnosinemia in carnosinase deficiency (genetic condition), Zinc chelation may reduce zinc availability at very high doses | Generally well-tolerated in animal studies, No significant adverse effects reported at research doses, Potential interaction with GH/IGF-1 axis (IGF-1 suppresses humanin production), Long-term human safety data limited |
| Cited sources | 2 references | 3 references |
Key differences
- Administration: Carnosine — Oral (capsule/powder), Topical (eye drops — cataract research); Humanin — Subcutaneous injection, Intranasal (for CNS applications), Intravenous (clinical studies).
- Dosing units differ: Carnosine is dosed in mg, Humanin in mcg — they operate at different scales.
- Frequency: Carnosine is typically twice daily oral; Humanin is Daily or 3–5x weekly.
- Research depth: this profile cites 2 sources for Carnosine vs 3 for Humanin.
How each works
Carnosine
Carnosine's multi-mechanism activity explains interest across several research domains. Its histidine moiety buffers intramuscular pH during high-intensity exercise, directly improving performance. As an anti-glycation agent, carnosine quenches reactive carbonyl species that form advanced glycation end-products (AGEs), potentially slowing protein crosslinking associated with tissue aging. Brain carnosine concentrations correlate with cognitive vitality in aging research.
Humanin
Humanin acts through multiple receptors (CNTFR/WSX-1/gp130 trimeric complex and FPRL1) to exert neuroprotection, cardioprotection, and metabolic effects. Key findings: humanin inhibits neuronal apoptosis in Alzheimer's disease models by blocking IGFBP-3 death signaling, reduces cardiovascular disease markers in clinical studies, improves insulin sensitivity in diabetic models, and reduces oxidative stress. IGF-1 downregulates humanin production — individuals on GH/IGF-1 therapies may have suppressed endogenous humanin. Centenarians have elevated humanin levels compared to age-matched controls.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.